Minerva Neurosciences (NASDAQ:NERV) Shares Pass Above 50-Day Moving Average of $2.65

Minerva Neurosciences, Inc. (NASDAQ:NERVGet Free Report) shares passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $2.65 and traded as high as $3.65. Minerva Neurosciences shares last traded at $3.51, with a volume of 23,018 shares traded.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on NERV shares. HC Wainwright decreased their target price on Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating on the stock in a report on Thursday, May 2nd. StockNews.com started coverage on Minerva Neurosciences in a report on Wednesday. They issued a “sell” rating on the stock.

Get Our Latest Report on NERV

Minerva Neurosciences Price Performance

The firm has a market cap of $24.06 million, a PE ratio of -0.77 and a beta of 0.13. The business has a fifty day moving average price of $2.69 and a two-hundred day moving average price of $4.75.

Minerva Neurosciences (NASDAQ:NERVGet Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.07. As a group, sell-side analysts forecast that Minerva Neurosciences, Inc. will post -1.89 EPS for the current fiscal year.

About Minerva Neurosciences

(Get Free Report)

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.

Featured Stories

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.